medalphabetМедицинский алфавитMedical alphabet2078-56312949-2807ООО «Альфмед»medalphabet-632Research ArticleСтатьиРационализация адъювантной химиотерапии рака ободочной кишкиRationalization of adjuvant chemotherapy for colon cancerДоброваН. В.DobrovaN. V.noemail@neicon.ruБорисоваЕ. И.BorisovaE. I.noemail@neicon.ruГуторовС. Л.GutorovS. L.noemail@neicon.ruЖуковаЛ. Г.ZhukovaL. G.noemail@neicon.ruФГБУ «Национальный медицинский исследовательский центр онкологии имени Н. Н. Блохина» Минздрава РоссииРоссияNational Medical Research Center of Oncology named after N. N. BlokhinRussian Federation201816052018115Диагностика и онкотерапия1215Copyright © Доброва Н.В., Борисова Е.И., Гуторов С.Л., Жукова Л.Г., 20182018Доброва Н.В., Борисова Е.И., Гуторов С.Л., Жукова Л.Г.Dobrova N.V., Borisova E.I., Gutorov S.L., Zhukova L.G.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-alphabet.com/jour/article/view/632

На основании новых данных клинических исследований рассматриваются вопросы о рациональной длительности адъювантной терапии рака ободочной кишки в зависимости от стадии и молекулярных характеристик опухоли. Представленные результаты потенциально влияют на клиническое решение при выборе режима и оптимального срока адъювантного лечения.

Basing on new clinical trials data, the optimal duration of colon cancer adjuvant therapy is considered depending on molecular characteristics and pathologic tumor staging. The presented results potentially influence the clinical decision on chemotherapy regimen choice and optimal duration of adjuvant treatment.

рак ободочной кишкиадъювантная химиотерапиядлительностьcolon canceradjuvant chemotherapydurationReferencesAndre T., Boni C., Navarro M., et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009; 27:3109-3116 / André T., Boni C., Mouned-ji-Boudiaf L., et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004 Jun 3; 350 (23): 2343-51.Andre T., Boni C., Navarro M., et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009; 27:3109-3116 / André T., Boni C., Mouned-ji-Boudiaf L., et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004 Jun 3; 350 (23): 2343-51.Park S. B., Goldstein D., Krishnan A. V., et al. Chemotherapy-induced peripheral neurotoxicify: a critical analysis. CA Cancer J Clin. 2013; 63: 419-437.Park S. B., Goldstein D., Krishnan A. V., et al. Chemotherapy-induced peripheral neurotoxicify: a critical analysis. CA Cancer J Clin. 2013; 63: 419-437.André T., Iveson T., Labianca R., et al. The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 months) Regimen for Patients with Stage III Colon Cancer: Trial Design and Current Status. Curr Colorectal Cancer Rep. 2013; 9: 261-269.André T., Iveson T., Labianca R., et al. The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 months) Regimen for Patients with Stage III Colon Cancer: Trial Design and Current Status. Curr Colorectal Cancer Rep. 2013; 9: 261-269.Shi Q., Sobrero A. F., Shields A. F., et al. Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration. Journal of Clinical Oncology 2017 35:18_suppl, LBA1-LBA1.Shi Q., Sobrero A. F., Shields A. F., et al. Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration. Journal of Clinical Oncology 2017 35:18_suppl, LBA1-LBA1.Taieb J., Kourie H. R., Emile J. F., et al. Association of Prognostic Value of Primary Tumor Location in Stage III Colon Cancer With RAS and BRAF Mutational Status. JAMA Oncol. 2017 Nov 22. doi: 10,1001/jamaon-col.2017.3695. [Epub ahead of print].Taieb J., Kourie H. R., Emile J. F., et al. Association of Prognostic Value of Primary Tumor Location in Stage III Colon Cancer With RAS and BRAF Mutational Status. JAMA Oncol. 2017 Nov 22. doi: 10,1001/jamaon-col.2017.3695. [Epub ahead of print].Saunders M. P., Paul J., Crosby J., et al. SCOT: Tumor sidedness and the influence of chemotherapy duration on DFS. Journal of Clinical Oncology 2018 36:4_suppl, 558-558.Saunders M. P., Paul J., Crosby J., et al. SCOT: Tumor sidedness and the influence of chemotherapy duration on DFS. Journal of Clinical Oncology 2018 36:4_suppl, 558-558.Gill S., Loprinzi C. L., Sargent D. J., et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol 2004; 22: 1797.Gill S., Loprinzi C. L., Sargent D. J., et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol 2004; 22: 1797.Samowitz W. S., Sweeney C., Herrick J. et al. Poor Survival Associated with the BRAF V600E Mutation in Microsatellite-Stable Colon Cancers. Cancer Res 2005; 65 (14): 6063-6069.Samowitz W. S., Sweeney C., Herrick J. et al. Poor Survival Associated with the BRAF V600E Mutation in Microsatellite-Stable Colon Cancers. Cancer Res 2005; 65 (14): 6063-6069.Popovici VC, Budinska E, Roth A, et al. BRAF and KRAS mutations as additional risk factors in the conte xt of clinical parameters of patients with colorectal cancer (abstract). J Clin Oncol 31, 2013 (suppl; abstr 3522).Popovici VC, Budinska E, Roth A, et al. BRAF and KRAS mutations as additional risk factors in the conte xt of clinical parameters of patients with colorectal cancer (abstract). J Clin Oncol 31, 2013 (suppl; abstr 3522).André T., de Gramont A., Vernerey D., et al. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study. J Clin Oncol 2015; 33: 4176.André T., de Gramont A., Vernerey D., et al. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study. J Clin Oncol 2015; 33: 4176.

The authors declare that there are no conflicts of interest present.